JAG1 and cancer: For instance, the Notch pathway is aberrantly activated in some malignant tumors, such as colorectal, breast and lung carcinomas, and play the tumor-facilitative role, which the inappropriate activation of Notch in these tumors is caused by a dysbalance between Notch ligands, such as Jagged1 and inhibitors [34, 35].